Electrolytes and electrolyte additives for energy storage devices comprising functional thiophene compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte, and at least one electrolyte additive selected from a thiophene compound.

Electrolytes and electrolyte additives for energy storage devices comprising functional thiophene compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte, and at least one electrolyte additive selected from a thiophene compound.

The present invention relates to a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of autophagy-related diseases.

The present invention relates to a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of autophagy-related diseases.

The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.

##STR00001##

The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.

##STR00001##

The invention provides a compound of formula (I):

##STR00001##

or a salt thereof, wherein R.sup.1 and R.sup.2 have any of the values defined in the specification, as well as methods of using such compounds and salts to separate an aryl compound from a mixture.

The invention provides a compound of formula (I):

##STR00001##

or a salt thereof, wherein R.sup.1 and R.sup.2 have any of the values defined in the specification, as well as methods of using such compounds and salts to separate an aryl compound from a mixture.

Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.

Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.